Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Axsome Thera (NQ: AXSM )

41.21 UNCHANGED
Streaming Delayed Price Updated: 4:00 PM EDT, Jul 5, 2022 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 6,987
Open 41.21
Bid (Size) 40.76 (1)
Ask (Size) 41.72 (2)
Prev. Close 41.21
Today's Range 41.21 - 41.21
52wk Range 19.38 - 66.26
Shares Outstanding 38,913,550
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
ROSEN, A LEADING LAW FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses Over $100K to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire
ROSEN, A LEADING NATIONAL FIRM, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important July 12 Deadline in Securities Class Action - AXSM
Search for the latest press releases from publicly traded companies, private corporations, non-profits and other public sector organizations. 
Via NewMediaWire

Performance

YTD
+8.93%
+8.93%
1 Month
+58.68%
+58.68%
3 Month
-11.85%
-11.85%
6 Month
+14.76%
+14.76%
1 Year
-37.01%
-37.01%

More News

Read More
What SVB Says On Axsome's Strategy Review On Sunosi For Sleeping Disorder
Via Benzinga
Analyst Ratings for Axsome Therapeutics
Via Benzinga
The Daily Biotech Pulse: CHMP Backs AstraZeneca's Breast Cancer Therapies, Ipsen Buys Epizyme, FDA Holds For Nuvation Bio, Astellas Studies
Via Benzinga
Global Pancreatic Cancer Therapeutics & Diagnostics Market Expected To Reach $5.6 Billion By 2027
Via FinancialNewsMedia
EV Stocks TSLA, NIO, RIVN See Price Targets Slashed
Via InvestorPlace
Axsome Therapeutics Rallies 40% On FDA Product Label Proposal, But Analyst Remains Skeptical
Via Benzinga
This Healthcare Stock Jumps Around 188%, Here's 83 Biggest Movers From Yesterday
Via Benzinga
Axsome Therapeutics Just Took Its Key Moving Averages — Here's Why
Via Investor's Business Daily
Why Is NeuroSense Therapeutics Surging By 70%? 46 Stocks Moving In Monday's Mid-Day Session
Via Benzinga
Axsome Therapeutics (AXSM) Stock Soars on FDA Labeling Proposal
Via InvestorPlace
U.S. Markets Open Lower; Durable Goods Orders Rise 0.7%
Via Benzinga
Why Axsome Therapeutics Stock Is Soaring Today
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
Via Benzinga
GLOBALLY RECOGNIZED ROSEN LAW FIRM Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal
ROSEN, RECOGNIZED INVESTOR COUNSEL, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Small-Cap Psychedelic Play Vying for Future Leadership in Addiction Treatment (AXSM, AWKNF, BICX, OPNT, ALKS, PFE, AMPH, OMER)
Via AB Newswire
6 Biotech Stocks to Buy Now Ahead of These June Catalysts
Via InvestorPlace
Axsome Therapeutics, Inc. Investor News: Robbins LLP is Investigating Axsome Therapeutics, Inc. (AXSM) on Behalf of Shareholders
From Robbins LLP
Via Business Wire
NATIONALLY RANKED ROSEN LAW FIRM Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action - AXSM
Via NewMediaWire
Topics Lawsuit
Exposures Financial Legal Product Safety
Glancy Prongay & Murray LLP Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
From Glancy Prongay & Murray LLP
Via Business Wire
Deadline Reminder: Law Offices of Howard G. Smith Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Axsome Therapeutics, Inc. (AXSM)
From Law Offices of Howard G. Smith
Via Business Wire
ROSEN, NATIONAL TRIAL LAWYERS, Encourages Axsome Therapeutics, Inc. Investors with Losses to Secure Counsel Before Important Deadline in Securities Class Action – AXSM
From The Rosen Law Firm, P.A.
Via Business Wire
The Law Offices of Frank R. Cruz Announces the Filing of a Securities Class Action on Behalf of Axsome Therapeutics, Inc. (AXSM) Investors
From The Law Offices of Frank R. Cruz
Via Business Wire
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.